allgemeines
| Adriamycin | 40 mg/qm | i.v. | d1 |
| Cyclophosphamid | 1g/qm | i.v. | d3, d4, d5, d6 |
| max 500-550mg Adriamycin | q22 |
| Adriamycin | 40 mg/qm | i.v. | d1 |
| Cyclophosphamid | 200mg/qm | p.o. | d3, d4, d5, d6 |
| max 500-550mg Adriamycin | q22-29 |
| Fluorouracil | 500 mg/qm |
| Epirubicin | 100 mg/qm |
| Cyclophosphamid | 500 mg/qm |
| 5-FU | 500 mg/qm | i.v. | d1, d8 |
| Adriamycin | 50 mg/qm | i.v. | d1 |
| Cyclophosphamid | 500mg/qm | i.v. | d1 |
| max 500-550mg Adriamycin | 3x q22, dann q29 |
| Adriamycin | 75 mg/qm | i.v. | d1 |
| Vincristin | 1,4mg/qm | i.v. | d1,d8 |
| q22 |
| Vincristin | 1mg/qm. max. 2mg | i.v. | d1 |
| Adriamycin | 40 mg/qm | i.v. | d1 |
| Cyclophosphamid | 200mg/qm | p.o.. | d3, d4, d5, d6 |
| max 500-550mg Adriamycin | 3x q22, dann q29 |
| Epirubicin | 150mg/qm | i.v. | alle 14 Tage | 3x dann: |
| Paclitaxel | 220 mg/qm | i.v. | alle 14 Tage | 3x dann: |
| Cyclophosphamid | 2000mg/qm | i.v. | alle 14 Tage | 3x |
| Sehr hartes Schema! Nur mit G-CSF-Gaben durchzuhalten | ||||
| Cyclophosphamid | 500 mg/qm |
| Methotrexat | 40 mg/qm |
| Fluorouracil | 600 mg/qm |
| Wiederholung | Tag 1, Tag 22 |
| Cyclophosphamid | 100 mg/qm | per os | d 1-14 |
| Methotrexat | 40 mg/qm | i.v. | d1, d8 |
| Fluorouracil | 600 mg/qm | i.v. | d1, d8 |
| Wiederholung | q29 |
| Cyclophosphamid | 100 mg/qm | per os | d 1-14 |
| Methotrexat | 30 mg/qm | per os, 4 geteilte Dosen | d1, d8 |
| Fluorouracil | 500 mg/qm | per os, 4 geteilte Dosen | d1, d8 |
| Wiederholung | q29 |
single shot
| Cyclophosphamid | 600 mg/qm |
| Methotrexat | 40 mg/qm |
| Fluorouracil | 600 mg/qm |
| Wiederholung | Tag 1, Tag 8, Tag 29 |
| Cyclophosphamid | 2 mg/kg | per os | täglich |
| Methotrexat | 0,5 mg/kg | i.v. | 1x / Woche |
| Prednisolon | 1 mg/kg | per os | 14 Tage, dann 25mg, später 10mg |
| Vincristin | 0,0251mg/kg | i.v. | 1x/W 4 Wochen, dann alle 8 Wochen |
| 5-FU | 10mg/kg | i.v. | 1x/W |
| Chlorambucil | 5 mg/qm | per os | täglich, 14 Tage lang |
| Methotrexat | 15 mg/qm | per os | 3 Tage / Woche, 2 Wochen lang |
| Prednisolon | 1 mg/kg | per os | 14 Tage, dann 14 Tage Pause |
| Vincristin | 1mg/qm, max. 2mg | i.v. | 1x/W, 3. und 4. Woche |
| 5.FU | 500mg/qm | i.v. | 1x/W, 3. und 4. Woche |
| Cyclophosphamid | 6 mg/kg | per os | täglich |
| Methotrexat | 0,12 mg/kg | per os | 3 Tage / Woche |
| Prednisolon | 1 mg/kg | per os | 14 Tage, dann Dosis auf 50% reduzieren, dann 0,25mg/kg |
Combination chemotherapy as an adjuvant treatment in operable breast cancer.
New Engl. J. Med. 294, 405-410 (1976)
2.) BRAMBILLA, C., DE LENA, M., ROSSI, A., VALAGUSSA, P.,BONADONNA, G.:
Response and survival in advanced breast cancer after two non-cross-resistant combinations.
Brit. med. J. 1, 801-804 (1976)
3.) BRAMBILLA, C., VALAGUSSA, P., BONADONNA, G.:
Sequential combination chemotherapy in advanced breast cancer.
Cancer Chemother. Pharmacol. 1, 35-39 (1978)
4.) BROWN, I., WARD, H. W. C.:
Doxorubicin in the treatment of advanced breast cancer; comparative studies of three combination chemotherapy regimes.
Clin. Oncology 2,105-111 (1976)
5.) BRUNNER, K. W.:
Present status of combination chemotherapy in advanced breast cancer.
Antibiotics Chemother. 24,173-188 (1978)
6.) BRUNNER, K.W.:
Stand der Hormon- und Chemotherapie beim Mammakarzinom.
Schweiz. med. Wschr. 108, 1338-1350 (1978)
7.) BRUNNER, K. W., MARTZ, G., SENN, H. J., OBRECHT, P., ALBERTO, P., MELCHERT, F.:
Kontrollierte Untersuchungen Ober cytostatische Kombinationstherapien beim metastasierenden Mammacarcinom.
Internist 14, 643-652 (1973)
8.) CANNELLOS, G. P., DE VITA, V.T., GOLD, G. L., CHABNER, B. A., SCHEIN, P. S., YOUNG, R. C.:
Cyclical combination chemotherapy for advanced breast carcinoma.
Brit. med. J. 1, 218-220 (1974)
9.) CARBONE, P. P., DAVIS, T. E.:
Medical treatment for advanced breast cancer.
Seminars in Oncology 5, 4 (1978)
10.) CARDENAS, J. O., BLUMENSCHEIN, G. R., GUTTERMAN, J. U., FREIREICH, E. J., GOTTLIEB, J. A.:
Sequential combination chemoimmunotherapy for advanced metastatic breast carcinoma.
Proc. Amer. Ass. Cancer Res. & Amer. Soc. clin. Oncol. 16, 231, ASCO Abstr. 1041 (1975)
11.) CARTER, S. K.:
Chemotherapy in advanced breast cancer.
Int. J. Radiation Oncology Biol. Phys. 4, 309-311 (1978)
12.) CARTER, S. K.:
Integration of chemotherapy into combined modality treatment of solid tumors. VII. Adenocarcinoma of the breast.
Cancer Treatment Rev. 3, 141-174 (1976)
13.) CAVALLI, F., ALBERTO, P., JUNGI, W. F., MARTZ, G., BARRELET, L., OBRECHT, J. P., BRUNNER, K.W.:
Gleichzeitige Hormon- und Chemotherapie, verglichen mit Hormontherapie, gefolgt von Chemotherapie, bei der Behandlung des metastasierenden Mammakarzinoms.
Schweiz. med. Wschr. 108, 1964-1966 (1978)
14.) CORDER, M. P., STONE, W. H., JUSTICE, G. R., HERBST, K. D., FLANNERY, E. P.:
Combination chemotherapy with or without leucovorin in the treatment of poor risk breast cancer patients.
Proc. Amer. Ass. Cancer Res. & Amer. Soc. clin. Oncol. 16, 202 AACR Abstr. 805 (1975)
15.) CREECH, R. H., CATALANO, R. B., HARRIS, D. T., ENGSTROM, P. F., GROTZINGER, P. J.:
Low dose chemotherapy of metastatic breast cancer with Cyclophosphamide, Adriamycin, Methotrexate, 5-Fluoruracil (CAMF) versus sequential Cyclophosphamide, Methotrexate, 5-Fluoruracil (CMF) and Adriamycin.
Cancer 43, 51-59 (1979)
16.) DESAI, S., TAYLOR; S., GOLDSWEIG, H., De WYS, W..
A phase 11 study of melphalan, methotrexate and 5-FU in breast cancer.
Proc. Amer. Ass. Cancer Res. & Amer. Soc. clin. Oncol 17, 303 ASCO Abstr. C 268 (1976)
17.) FALKSON, G., FALSON, H. C., GLIDEWELL, 0., WEINBERG, V., LEONE, L., HOLLAND, J. F.:
Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy. Cancer 43, 2215-2222 (1979)
18.) GALLMEIER, W. M., BRUNTSCH, U., SCHMIDT, C. G.:
Die Chemotherapie des metastasierenden Mammakarzinoms.
Med. Welt 27, 1042-1047 (1976)
19.) HOFFKEN, K., SEEBER, S., BOECKER, W. R., SCHMIDT, C. G.:
Adriamycin, Cyclophosphamid und Fluorouracil in der Therapie des metastasierenden Mamma-Carcinoms.
Z. Krebsforsch. 86, 135-145 (1976)
20.) HORTOBAGYI, G. N., GUTTERMAN, J. U., BLUMENSCHEIN, G. R., YAP, H. Y., BUZDAR, A. U., TASHIMA, CH. K., BURGESS, M. A., HERSH, E. M.:
Combined chemoimmunotherapy for advanced breast cancer.
Cancer 43, 1112-1122 (1979)
21.) KENNEALEY, G. T., BOSTON, B., MITCHELL, M. S., KNOBF, M. K., BROBROW, S. N., PEZZIMENTI, J. F., LAWRENCE, R., BERTINO, J. R.:
Combination chemotherapy for advanced breast cancer.
Cancer 42, 27-33 (1978)
22.) RAINEY, J. M., JONES, S. E., SALMON, S. E.:
Combination chemotherapy for advanced breast cancer utilizing Vincristine, Adriamycin, and Cyclophosphamide (VAC).
Cancer 43 (1979): 66-71
23.) SALMON, S. E., JONES, S. E.:
Chemotherapy of advanced breast cancer with a combination of adriamycin and cyclophosphamide.
Proc. Amer. Ass. Cancer Res. & Amer. Soc. clin. Oncol. 15, 90, AACR Abstr. 359 (1974)
24.) SEEBER, S.:
Internistische Therapie des metastasierenden Mammakarzinoms.
Klinikarzt 6 (1977):569-577
25.) SENN, H. J.:
Behandlungsfortschritte durch multimodale Therapie beim Mamma-Carcinom?
Schweiz. med. Wschr. 108 (1978):1938-1947
26.) SENN, H. J.:
Therapiefortschritte beim Mammakarzinom?
Klinikarzt 8 (1979): 348-362
27.) TASHIMA, C. K., BLUMENSCHEIN, G. R., GUTTERMAN, J. U.:
Comparison of Adriamycin combination drug program with BCG Immunotherapy vs. MER Immunotherapie for metastatic breast cancer.
Proc. Amer. Ass. Cancer Res. & Amer. Soc. clin. Oncol. 17, 288, ASCO Abstr. C 207 (1976)
28.) YAP, H. Y., BLUMENSCHEIN, G. R., TASHIMA, C. K., HORTOBAGYI, G. N., BUZDAR, A. U., WISEMAN, C. L.:
Combination chemotherapy with Vincristine and Methotrexate for advanced refractory breast cancer.
Cancer 44 (1979): 32-34
